Understanding bacterial biofilms in patients with cystic fibrosis: Current and innovative approaches to potential therapies

Journal of Cystic Fibrosis

Volumn 1, Issue 4, 2002, Pages 249-254

  Høiby, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bacteria; Biofilms; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

ACETYLCYSTEINE; ALGINIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAM ANTIBIOTIC; BUDESONIDE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; GLUCURONIC ACID; HEXURONIC ACID; IBUPROFEN; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN RADICAL; PIPERACILLIN; PIROXICAM; PREDNISONE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; BACTERIAL SURVIVAL; BIOFILM; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFECT; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INFLAMMATION; LUNG INFECTION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT;

ALGINATES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0036897745     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-1993(02)00104-2     Document Type: Review

References (46)

1. Høiby N, Johansen HK, Moser C, Song ZJ, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the biofilm mode of growth. Microbes Infect. 2001;3:1-13.
2. Baltimore RS, Christie CDC, Smith GJW. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis - implications for the pathogenesis of progressive lung deterioration. ARRD 1989;140:1650-61.
3. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002;109(3):317-25.
4. Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology UK 1999;145:1349-57.
5. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407(6805):762-4.
6. Domingue G, Ellis B, Dasgupta M, Costerton JW. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards. J. Clin. Microbiol. 1994;32(10):2564-8.
7. Nichols WW, Dorrington SM, Slack MPE, Walmsley HL. Inhibition of Tobramycin diffusion by binding to alginate. Antimirobial Agents Chemother. 1988;32:518-23.
8. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob. Agents Chemother. 1992;36:1347-51.
9. Ciofu O, Beveridge TJ, Kadurugamuwa J, WaltherRasmussen J, Høiby N. Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000;45(1):9-13.
10. 2O2. (Abstract)Pediatr. Pulmonol. 2000;(Suppl. 20):273.
11. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358(9276):135-8.
12. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. ARRD 1990;141:914-21.
13. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121(1):55-63.
14. Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Resp. J. 2000;16(4):749-67.
15. Ciofu O, Fussing V, Bagge N, Koch C, Høiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from danish cystic fibrosis patients: antibiotic resistance, β-lactamase activity and riboprinting. J. Antimicrob. Chemother. 2001;48(3):391-6.
16. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-3.
17. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Hoiby N. Rapid emergence of resistance in Pseudomonas-aeruginosa in cystic fibrosis patients due to invivo selection of stable partially derepressed beta-lactamase producing strains. J. Antimicrob. Chemother. 1990;26(2):247-59.
18. Giwercman B, Meyer C, Lambert PA, Reinert C, Høiby N. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob. Agents Chemother. 1992;36(1):71-6.
19. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 2000;44(3):710-2.
20. Moskowitz SM, Burns JL, Nguyen CD, Høiby N, Ernst RK, Miller SI. Polymyxin resistance and lipid A structure of Pseudomonas aeruginosa isolated from colistin-treated and colistin-naive cystic fibrosis patients. Pediatr. Pulmonol. 2000;(Suppl. 20):272 (Abstract).
21. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Collins CE, Garg ML. Oxidative stress in cystic fibrosis: dietary and metabolic factors. J. Am. Coll. Nutr. 2001;20(2):157-65.
22. Jensen T, Kharazmi A, Schiøtz PO, et al. Effect of oral N-acetylcystein administration on human blood neutrophil and monocyte function. Acta Pathol. Microbiol. Immunol. Scand. 1988;96:62-7.
23. Heinzl B, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on aquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 2002;33:32-7.
24. Whitchurch CB, TolkerNielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295(5559):1487.
25. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients wit cystic fibrosis. N. Engl. J. Med. 1999;340(1):23-30.
26. Anwar H, Strap JL, Chen K, Costerton JW. Dynamic interactions of biofilms of mucoid Pseudomonas-aeruginosa with tobramycin and piperacillin. Antimicrob. Agents Chemother. 1992;36(6):1208-14.
27. Sakata K, Yajima H, Tanaka K, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am. Rev. Respir. Dis. 1993;148(4):1061-5.
28. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas-aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 1993;31(5):681-8.
29. Kobayashi H. Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. J. Infect. Chemother. 1995;1:1-15.
30. Høiby N. New antimicrobials in the management of cystic fibrosis. J. Antimicrob. Chemother. 2002;49:235-8.
31. Hancock REW. Cationic antimicrobial peptides: towards clinical applications. Expert Opin. Invest. Drugs 2000;9(8):1723-9.
32. Krogfelt KA, Utley M, Krivan HC, Laux DC, Cohen PS. Specific phospholipids enhance the activity of beta-lactam antibiotics against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000;46(3):377-84.
33. Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1998;42(4):974-7.
34. Jass J, LappinScott HM. The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms. J. Antimicrob. Chemother. 1996;38(6):987-1000.
35. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 2002;57:212-6.
36. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, VanDelden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2001;45(6):1930-3.
37. Rasmussen TB, Manefield M, Andersen JB, et al. How Delisea pulchra furanones affect quorum sensing and swarming motility in Serratia liquefaciens MG1. Microbiology UK 2000;146:3237-44.
38. Eigen H, Rosenstein BJ, Fitzsimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J. Pediatr. 1995;126(4):515-23.
39. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of highdose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 1995;332(13):848-54.
40. Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC. A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int. J. Immunopathol. Pharmacol. 1994;7(2):109-17.
41. Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 1997;156(4):1190-6.
42. Sauer K, Camper AK, Erlich GD, Costerton JW, Davis DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J. Bact. 2002;189(4):1140-54.
43. Middleton B, Rodgers HC, Camara M, Knox AJ, Williams P, Hardman A. Detection of N-acylhomoserine lactones in cysic fibrosis sputum. FEMS Microbial. Lett. 2002;207(1):1-7.
44. FavreBonte S, Pache JC, Robert J, Blanc D, Pechere JC, van Delden C. Detection of Pseudomonas aeruginosa cell-to-cell signals in lung tissue of cystic fibrosis patients. Microb. Pathog. 2002;32(3):143-7.
45. Wu H, Sonf Z, Hentzer M, et al. Detection of N-acylhomoserine lactones in lung tissue of mice infected with Pseudomonas aeruginosa. Microbiology 2000;146:2481-93.
46. Wu H, Song Z, Givskov M, et al. Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology 2001;147:1105-13.